Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Active | |||
| Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | ||
| Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
| Somavert | Pegvisomant | acromegaly | Do not list | Complete | ||
| Somatuline Autogel | Lanreotide acetate | Acromegaly | List in a similar manner to other drugs in class | Complete | ||
| Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
| Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
| Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
| Ultomiris | ravulizumab | AChR antibody-positive generalized Myasthenia Gravis | Do not reimburse | Complete | ||
| Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 15, 2024